{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:06:03Z","timestamp":1786982763960,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T00:00:00Z","timestamp":1683676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T00:00:00Z","timestamp":1683676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s40268-023-00420-y","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T05:22:50Z","timestamp":1683782570000},"page":"129-140","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety and Effectiveness of Rasburicase in the Control of Hyperuricemia in Pediatric Patients with Non-Hodgkin\u2019s Lymphoma and Acute Leukemia: An Open-Label, Single-Arm, Multi-center, Interventional Study"],"prefix":"10.1007","volume":"23","author":[{"given":"Tianyou","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongmin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingyi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianpei","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinchuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minlu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,10]]},"reference":[{"key":"420_CR1","unstructured":"Adeyinka A, Bashir K. Tumor Lysis Syndrome. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2021. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK518985\/. Accessed 2 Dec 2021."},{"key":"420_CR2","first-page":"e6375693","volume":"2019","author":"PT Myint","year":"2019","unstructured":"Myint PT, Butt HW, Alrifai T, Marin C. Spontaneous tumor lysis syndrome secondary to small-cell neuroendocrine carcinoma of unknown origin: a rare case report and literature review. Case Rep Oncol Med. 2019;2019:e6375693.","journal-title":"Case Rep Oncol Med"},{"key":"420_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-2141.2004.05094.x","volume":"127","author":"MS Cairo","year":"2004","unstructured":"Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004;127:3\u201311.","journal-title":"Br J Haematol"},{"key":"420_CR4","doi-asserted-by":"publisher","first-page":"4402","DOI":"10.1200\/JCO.2003.04.115","volume":"21","author":"B Coiffier","year":"2003","unstructured":"Coiffier B, Mounier N, Bologna S, Ferm\u00e9 C, Tilly H, Sonet A, et al. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-hodgkin\u2019s lymphoma: results of the GRAAL1 (Groupe d\u2019Etude des Lymphomes de l\u2019Adulte Trial on Rasburicase Activity in Adult Lymphoma) Study. J Clin Oncol. 2003;21:4402\u20136.","journal-title":"J Clin Oncol"},{"key":"420_CR5","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1159\/000320581","volume":"33","author":"B Coiffier","year":"2010","unstructured":"Coiffier B. Acute tumor lysis syndrome\u2014a rare complication in the treatment of solid tumors. Onkologie. 2010;33:498\u20139.","journal-title":"Onkologie"},{"key":"420_CR6","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1080\/1042819021000054661","volume":"44","author":"L Annemans","year":"2003","unstructured":"Annemans L, Moeremans K, Lamotte M, Garcia Conde J, van den Berg H, Myint H, et al. Incidence, medical resource utilisation and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin\u2019s lymphoma in four European countries. Leuk Lymphoma. 2003;44:77\u201383.","journal-title":"Leuk Lymphoma"},{"key":"420_CR7","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1200\/JCO.2007.15.0177","volume":"26","author":"B Coiffier","year":"2008","unstructured":"Coiffier B, Altman A, Pui C-H, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26:2767\u201378.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"key":"420_CR8","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1111\/bjh.13403","volume":"169","author":"GL Jones","year":"2015","unstructured":"Jones GL, Will A, Jackson GH, Webb NJA, Rule S, British Committee for Standards in Haematology. Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology. Br J Haematol. 2015;169:661\u201371.","journal-title":"Br J Haematol"},{"key":"420_CR9","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/pbc.20555","volume":"46","author":"HY Shin","year":"2006","unstructured":"Shin HY, Kang HJ, Park ES, Choi HS, Ahn HS, Kim SY, et al. Recombinant urate oxidase (Rasburicase) for the treatment of hyperuricemia in pediatric patients with hematologic malignancies: results of a compassionate prospective multicenter study in Korea. Pediatr Blood Cancer. 2006;46:439\u201345.","journal-title":"Pediatr Blood Cancer"},{"key":"420_CR10","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1007\/s12185-009-0402-6","volume":"90","author":"A Kikuchi","year":"2009","unstructured":"Kikuchi A, Kigasawa H, Tsurusawa M, Kawa K, Kikuta A, Tsuchida M, et al. A study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome. Int J Hematol. 2009;90:492\u2013500.","journal-title":"Int J Hematol"},{"key":"420_CR11","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13045-019-0785-7","volume":"12","author":"W Liu","year":"2019","unstructured":"Liu W, Liu J, Song Y, Zeng X, Wang X, Mi L, et al. Burden of lymphoma in China, 2006\u20132016: an analysis of the Global Burden of Disease Study 2016. J Hematol OncolJ Hematol Oncol. 2019;12:115.","journal-title":"J Hematol OncolJ Hematol Oncol."},{"key":"420_CR12","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/ped4.12210","volume":"4","author":"C Li","year":"2020","unstructured":"Li C, Tang J, Zheng H, Fang J, Sun X. Treatment of childhood cancer in China: current status and future direction. Pediatr Investig. 2020;4:153\u20136.","journal-title":"Pediatr Investig."},{"key":"420_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jama.1965.03090010007001","volume":"193","author":"IH Krakoff","year":"1965","unstructured":"Krakoff IH. Prevention of hyperuricemia in leukemia and lymphoma: use of allopurinol, a xanthine oxidase inhibitor. JAMA. 1965;193:1.","journal-title":"JAMA"},{"key":"420_CR14","doi-asserted-by":"publisher","first-page":"597","DOI":"10.2147\/OTT.S103864","volume":"10","author":"N Alakel","year":"2017","unstructured":"Alakel N, Middeke JM, Schetelig J, Bornh\u00e4user M. Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase. OncoTargets Ther. 2017;10:597\u2013605.","journal-title":"OncoTargets Ther."},{"key":"420_CR15","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2147\/BTT.S1522","volume":"2","author":"A Pession","year":"2008","unstructured":"Pession A, Melchionda F, Castellini C. Pitfalls, prevention, and treatment of hyperuricemia during tumor lysis syndrome in the era of rasburicase (recombinant urate oxidase). Biol Targets Ther. 2008;2:129\u201341.","journal-title":"Biol Targets Ther."},{"key":"420_CR16","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1186\/2193-1801-3-395","volume":"3","author":"R Fazel","year":"2014","unstructured":"Fazel R, Zarei N, Ghaemi N, Namvaran MM, Enayati S, Mirabzadeh Ardakani E, et al. Cloning and expression of Aspergillus flavus urate oxidase in Pichia pastoris. Springerplus. 2014;3:395.","journal-title":"Springerplus"},{"key":"420_CR17","doi-asserted-by":"publisher","first-page":"83","DOI":"10.7150\/ijms.4.83","volume":"4","author":"L Cammalleri","year":"2007","unstructured":"Cammalleri L, Malaguarnera M. Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout. Int J Med Sci. 2007;4:83\u201393.","journal-title":"Int J Med Sci"},{"key":"420_CR18","first-page":"23","volume":"10","author":"J Dinnel","year":"2015","unstructured":"Dinnel J, Moore BL, Skiver BM, Bose P. Rasburicase in the management of tumor lysis: an evidence-based review of its place in therapy. Core Evid. 2015;10:23\u201338.","journal-title":"Core Evid."},{"key":"420_CR19","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1182\/blood.V97.10.2998","volume":"97","author":"SC Goldman","year":"2001","unstructured":"Goldman SC, Holcenberg JS, Finklestein JZ, Hutchinson R, Kreissman S, Johnson FL, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood. 2001;97:2998\u20133003.","journal-title":"Blood"},{"key":"420_CR20","doi-asserted-by":"publisher","first-page":"4207","DOI":"10.1200\/JCO.2009.26.8896","volume":"28","author":"J Cortes","year":"2010","unstructured":"Cortes J, Moore JO, Maziarz RT, Wetzler M, Craig M, Matous J, et al. Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone\u2013results of a multicenter phase III study. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28:4207\u201313.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"key":"420_CR21","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1080\/13696998.2019.1603155","volume":"22","author":"S Hu","year":"2019","unstructured":"Hu S, Han Y, Zhang W, Zhang T, Yao X, Liu L. Cost-effectiveness analysis of rasburicase over standard of care for the prevention and treatment of tumor lysis syndrome in children with hematologic malignancies in China. J Med Econ. 2019;22:742\u201350.","journal-title":"J Med Econ"},{"key":"420_CR22","doi-asserted-by":"publisher","first-page":"e99","DOI":"10.1016\/j.clml.2020.08.024","volume":"21","author":"G Gupta","year":"2021","unstructured":"Gupta G, Seth T, Garg V, Juneja R, Mahapatra M, Datta SK, et al. Efficacy of single low-dose rasburicase in management of tumor lysis syndrome in leukemia and lymphoma patients. Clin Lymphoma Myeloma Leuk. 2021;21:e99-104.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"420_CR23","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1007\/s12288-018-0938-9","volume":"34","author":"A Philips","year":"2018","unstructured":"Philips A, Radhakrishnan V, Ganesan P, Ganesan TS, Ramamurthy J, Dhanushkodi M, et al. Efficacy of single dose rasburicase (1.5 mg) for prophylaxis and management of laboratory tumor lysis syndrome. Indian J Hematol Blood Transfus Off J Indian Soc Hematol Blood Transfus. 2018;34:618\u201322.","journal-title":"Indian J Hematol Blood Transfus Off J Indian Soc Hematol Blood Transfus."},{"key":"420_CR24","first-page":"CD006945","volume":"2014","author":"DKL Cheuk","year":"2014","unstructured":"Cheuk DKL, Chiang AKS, Chan GCF, Ha SY. Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer. Cochrane Database Syst Rev. 2014;2014:CD006945.","journal-title":"Cochrane Database Syst Rev"},{"key":"420_CR25","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1517\/14712598.8.10.1595","volume":"8","author":"J Hochberg","year":"2008","unstructured":"Hochberg J, Cairo MS. Rasburicase: future directions in tumor lysis management. Expert Opin Biol Ther. 2008;8:1595\u2013604.","journal-title":"Expert Opin Biol Ther"},{"key":"420_CR26","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1038\/sj.leu.2402235","volume":"15","author":"CH Pui","year":"2001","unstructured":"Pui CH, Jeha S, Irwin D, Camitta B. Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial. Leukemia. 2001;15:1505\u20139.","journal-title":"Leukemia"},{"key":"420_CR27","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1345\/aph.1D111","volume":"37","author":"AC Lee","year":"2003","unstructured":"Lee AC, Li CH, So KT, Chan R. Treatment of Impending tumor lysis with single-dose rasburicase. Ann Pharmacother. 2003;37:1614\u20137.","journal-title":"Ann Pharmacother"},{"key":"420_CR28","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1007\/s11096-020-01144-8","volume":"42","author":"Y Pei","year":"2020","unstructured":"Pei Y, Li Y, Liang Y, Xu L, Huang X, Li Y, et al. Evaluation of the safety and efficacy of low-dose rasburicase in critically ill children with haematological malignancies. Int J Clin Pharm. 2020;42:1440\u20136.","journal-title":"Int J Clin Pharm"},{"key":"420_CR29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-2141.2004.05094.x","volume":"127","author":"MS Cairo","year":"2004","unstructured":"Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification: new therapeutic strategies and classification of TLS. Br J Haematol. 2004;127:3\u201311.","journal-title":"Br J Haematol"},{"key":"420_CR30","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/j.1365-2141.2010.08143.x","volume":"149","author":"MS Cairo","year":"2010","unstructured":"Cairo MS, Coiffier B, Reiter A, Younes A, Panel on behalf of the TE. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol. 2010;149:578\u201386.","journal-title":"Br J Haematol"},{"key":"420_CR31","unstructured":"Technical guidelines for clinical pharmacokinetic research of chemical drugs. 2005.https:\/\/www.cde.org.cn\/zdyz\/domesticinfopage?zdyzIdCODE=4247ffceca57f2b47aa0f67a3fdc7c43."},{"key":"420_CR32","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/j.1743-7563.2011.01464.x","volume":"7","author":"J Chiang","year":"2011","unstructured":"Chiang J, Chan A, Lian T, Tay K, Quek R, Tao M, et al. Management of tumor lysis syndrome with a single fixed dose of rasburicase in Asian lymphoma patients: a case series and literature review. Asia Pac J Clin Oncol. 2011;7:351\u20136.","journal-title":"Asia Pac J Clin Oncol"},{"key":"420_CR33","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1038\/sj.leu.2400850","volume":"11","author":"CH Pui","year":"1997","unstructured":"Pui CH, Relling MV, Lascombes F, Harrison PL, Struxiano A, Mondesir JM, et al. Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukemia. 1997;11:1813\u20136.","journal-title":"Leukemia"},{"key":"420_CR34","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s40264-014-0255-7","volume":"38","author":"KC Allen","year":"2015","unstructured":"Allen KC, Champlain AH, Cotliar JA, Belknap SM, West DP, Mehta J, et al. Risk of anaphylaxis with repeated courses of rasburicase: a Research on Adverse Drug Events and Reports (RADAR) project. Drug Saf. 2015;38:183\u20137.","journal-title":"Drug Saf"},{"key":"420_CR35","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.7573\/dic.2019-8-2","volume":"9","author":"WL Cheung","year":"2020","unstructured":"Cheung WL, Hon KL, Fung CM, Leung AK. Tumor lysis syndrome in childhood malignancies. Drugs Context. 2020;9:2019.","journal-title":"Drugs Context."},{"key":"420_CR36","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/sj.leu.2403566","volume":"19","author":"S Jeha","year":"2005","unstructured":"Jeha S, Kantarjian H, Irwin D, Shen V, Shenoy S, Blaney S, et al. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia. 2005;19:34\u20138.","journal-title":"Leukemia"},{"key":"420_CR37","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/bjh.12542","volume":"163","author":"PJ Galardy","year":"2013","unstructured":"Galardy PJ, Hochberg J, Perkins SL, Harrison L, Goldman S, Cairo MS. Rasburicase in the prevention of laboratory\/clinical tumour lysis syndrome in children with advanced mature B-NHL: a Children\u2019s Oncology Group Report. Br J Haematol. 2013;163:365\u201372.","journal-title":"Br J Haematol"},{"key":"420_CR38","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1002\/cncr.11612","volume":"98","author":"A Bosly","year":"2003","unstructured":"Bosly A, Sonet A, Pinkerton CR, McCowage G, Bron D, Sanz MA, et al. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study. Cancer. 2003;98:1048\u201354.","journal-title":"Cancer"},{"key":"420_CR39","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/BF02893442","volume":"13","author":"I R\u00e9nyi","year":"2007","unstructured":"R\u00e9nyi I, B\u00e1rdi E, Udvardi E, Kov\u00e1cs G, Bartyik K, Kajt\u00e1r P, et al. Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin\u2019s lymphoma. Pathol Oncol Res POR. 2007;13:57\u201362.","journal-title":"Pathol Oncol Res POR."},{"issue":"72","key":"420_CR40","first-page":"103","volume":"2010","author":"VS Tatay","year":"2003","unstructured":"Tatay VS, Castilla JDL, Ponce JMC, Hurtado JMP, Cantero EQ, Abril ML. Rasburicase versus allopurinol in the treatment of hyperuricaemia in tumour lysis syndrome. An Pediatr Barc Spain. 2003;2010(72):103\u201310.","journal-title":"An Pediatr Barc Spain"},{"key":"420_CR41","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1080\/08880018.2017.1348415","volume":"34","author":"KG Gopakumar","year":"2017","unstructured":"Gopakumar KG, Thankamony P, Seetharam S, Kusumakumary P. Treatment of tumor lysis syndrome in children with leukemia\/lymphoma in resource-limited settings-efficacy of a fixed low-dose rasburicase. Pediatr Hematol Oncol. 2017;34:206\u201311.","journal-title":"Pediatr Hematol Oncol"},{"key":"420_CR42","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1159\/000509934","volume":"45","author":"J Matuszkiewicz-Rowinska","year":"2020","unstructured":"Matuszkiewicz-Rowinska J, Malyszko J. Prevention and treatment of tumor lysis syndrome in the era of onco-nephrology progress. Kidney Blood Press Res. 2020;45:645\u201360.","journal-title":"Kidney Blood Press Res"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-023-00420-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-023-00420-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-023-00420-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T12:35:26Z","timestamp":1687782926000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-023-00420-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,10]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["420"],"URL":"https:\/\/doi.org\/10.1007\/s40268-023-00420-y","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,10]]},"assertion":[{"value":"29 March 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This phase IV trial was sponsored by Sanofi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Jinchuan Sun and Minlu Zhang are Sanofi employees and may hold shares and\/or stock options in the company. The other authors declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The datasets generated during and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The study protocol and its subsequent revisions were approved by the independent ethics committees (IECs) and\/or institutional review boards (IRBs) (IEC-C-007-A01-V.05), while conforming to the standards of the Declaration of Helsinki and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines for Good Clinical Practice (GCP), all applicable laws, rules, and regulations.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided written informed consent before study entry.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors provided substantial contributions to the interpretation of data for the work and read and approved the final version of the manuscript to be published.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}